A novel D-amino acid peptide with therapeutic potential (ISAD1) inhibits aggregation of neurotoxic disease-relevant mutant Tau and prevents Tau toxicity in vitro

Isabelle Aillaud(Coburg University of Applied Sciences), Senthilvelrajan Kaniyappan(University of Bonn), Ram Reddy Chandupatla(German Center for Neurodegenerative Diseases), Lisa Marie Ramirez(German Center for Neurodegenerative Diseases), Sewar Alkhashrom(Friedrich-Alexander-Universität Erlangen-Nürnberg), Jutta Eichler(Friedrich-Alexander-Universität Erlangen-Nürnberg), Anselm H. C. Horn(Friedrich-Alexander-Universität Erlangen-Nürnberg), Markus Zweckstetter(German Center for Neurodegenerative Diseases), Eckhard Mandelkow�(University of Bonn), Heinrich Sticht(Friedrich-Alexander-Universität Erlangen-Nürnberg), Susanne Aileen Funke(Coburg University of Applied Sciences)
Alzheimer s Research & Therapy
January 21, 2022
Cited by 32Open Access
Full Text

Abstract

Abstract Background Alzheimer’s disease (AD), the most common form of dementia, is a progressive neurodegenerative disorder that mainly affects older adults. One of the pathological hallmarks of AD is abnormally aggregated Tau protein that forms fibrillar deposits in the brain. In AD, Tau pathology correlates strongly with clinical symptoms, cognitive dysfunction, and neuronal death. Methods We aimed to develop novel therapeutic D-amino acid peptides as Tau fibrillization inhibitors. It has been previously demonstrated that D-amino acid peptides are protease stable and less immunogenic than L-peptides, and these characteristics may render them suitable for in vivo applications. Using a phage display procedure against wild type full-length Tau (Tau FL ), we selected a novel Tau binding L-peptide and synthesized its D-amino acid version ISAD1 and its retro inversed form, ISAD1rev, respectively. Results While ISAD1rev inhibited Tau aggregation only moderately, ISAD1 bound to Tau in the aggregation-prone PHF6 region and inhibited fibrillization of Tau FL , disease-associated mutant full-length Tau (Tau FLΔK , Tau FL-A152T , Tau FL-P301L ), and pro-aggregant repeat domain Tau mutant (Tau RDΔK ). ISAD1 and ISAD1rev induced the formation of large high molecular weight Tau FL and Tau RDΔK oligomers that lack proper Thioflavin-positive β-sheet conformation even at lower concentrations. In silico modeling of ISAD1 Tau interaction at the PHF6 site revealed a binding mode similar to those known for other PHF6 binding peptides. Cell culture experiments demonstrated that ISAD1 and its inverse form are taken up by N2a-Tau RDΔK cells efficiently and prevent cytotoxicity of externally added Tau fibrils as well as of internally expressed Tau RDΔK . Conclusions ISAD1 and related peptides may be suitable for therapy development of AD by promoting off-pathway assembly of Tau, thus preventing its toxicity.


Related Papers

No related papers found

Powered by citation graph analysis